ArchiMed chair Ribon moves to New York office

Alessia Argentieri
27 January 2021

Tweet
Facebook
LinkedIn
Google plus
Send to

ArchiMed chair Denis Ribon has moved from the firm's headquarters in Lyon to ArchiMed's New York office.

In addition, the firm has made five new hires to expand its New York City office, including the appointment of BC Partners' Justin Bateman as partner.

The other new hires are Carlos Alonso and Nick Pachuda, who have been appointed as strategic partners; Monica Holec, appointed as principal of investor relations; and Anthony Farias, hired as associate director.

Justin Bateman joined ArchiMed from BC Partners, where he worked for 20 years, becoming managing partner and co-founding the group's New York office in 2008. He was a member of BC's investment committee and led 14 transactions across North America and Europe amounting to approximately $3bn in invested capital, with an emphasis on the healthcare space.

Carlos Alonso has 30 years of international operating experience in the healthcare industry, most recently as international president at Hill-Rom Holdings.

Nick Pachuda is a former orthopaedics surgeon who spent the past 17 years developing new product strategies and cross-selling opportunities for a range of healthcare businesses. He most recently served as vice-president of orthopaedic innovation for Johnson and Johnson Medical Devices Group.

Monica Holec was previously a senior managing director and head of investor relations at Levine Leichtman Capital Partners, where she was responsible for internalising the investor relations and fundraising function, and managing the firm's LP relationships globally.

Anthony Farias previously worked as a private equity professional at MacAndrews & Forbes. He began his career at JP Morgan in the healthcare group.

"The US is a key market for us as our European investments derive most of their revenues from this side of the Atlantic," said ArchiMed chair Ribon. "Our proven success in this market was reinforced in 2020 by four completed investments across the healthcare IT, medical devices and CRO sectors."

ArchiMed is a European private equity firm dedicated to the healthcare industry, with a focus on the pharmaceuticals, medical devices and technology, healthcare IT and consumer health segments.

The firm currently manages nearly €2bn in assets across four funds: small-cap-focused MED I and MED II; gene- and cell-therapy-dedicated PolyMED; and mid-cap-focused MED Platform I, which closed on €1bn in August 2020, exceeding its €800m target.